Exelixis
EXEL
#1647
Rank
S$16.62 B
Marketcap
S$66.15
Share price
-2.52%
Change (1 day)
19.63%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): S$4.01

According to Exelixis's latest financial reports the company's current EPS (TTM) is S$4.03. In 2025 the company made an earnings per share (EPS) of S$3.72.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$4.017.88%
2025S$3.72
2023S$0.8414.61%
2022S$0.73-22.97%
2021S$0.95100%
2020S$0.48-65.09%
2019S$1.36-53.91%
2018S$2.96333.96%
2017S$0.68-260.61%
2016S-$0.42-58.75%
2015S-$1.03-42.45%
2014S-$1.795.3%
2013S-$1.70

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
S$11.25 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$1.69-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$18.64 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
S$3.30-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$4.58 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$4.58 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$5.00 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
S-$4.73-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S-$1.08-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA